1 Reduced antibody acquisition with increasing age following vaccination with

2 BNT162b2: results from a large study performed in the general population

3 aged 12 to 92 years

- 4 Lotus L. van den Hoogen¹, Mardi C. Boer¹, Abigail Postema¹, Lia de Rond¹, Mary-lène de Zeeuw-
- 5 Brouwer¹, Inge Pronk¹, Alienke J. Wijmenga-Monsuur¹, Elske Bijvank¹, Caitlyn Kruiper¹, Lisa Beckers¹,
- 6 Marjan Bogaard-van Maurik¹, Ilse Zutt¹, Jeffrey van Vliet¹, Rianne van Bergen¹, Marjan Kuijer¹, Gaby
- 7 Smits¹, W. M. Monique Verschuren, H. Susan J. Picavet, Fiona R.M. van der Klis¹, Gerco den Hartog¹,
- 8 Robert S. van Binnendijk¹, Anne-Marie Buisman¹
- 9

10 Affiliations:

- Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public
 Health and the Environment (RIVM), Bilthoven, The Netherlands
- 13 2. Centre for Prevention and Health Services Research, National Institute for Public Health and
- 14 the Environment (RIVM), Bilthoven, The Netherlands

15 Abstract

16 Vaccine-induced protection of the population against severe COVID-19, hospitalization and death is 17 of utmost importance, especially in the elderly. However, limited data are available on humoral 18 immune responses following COVID-19 vaccination in the general population across a broad age 19 range. We performed an integrated analysis of the effect of age, sex and prior SARS-CoV-2 infection 20 on Spike S1-specific (S1) IgG concentrations up to three months post BNT162b2 vaccination. 1.735 21 persons, eligible for COVID-19 vaccination through the national program, were recruited from the 22 general population (12 to 92 years old). Sixty percent were female and the median vaccination 23 interval was 35 days (interquartile range, IQR: 35-35). All participants had seroconverted to S1 one 24 month after two doses of vaccine. S1 IgG was higher in participants with a history of SARS-CoV-2 25 infection (median: 4.535 BAU/ml, IQR: 2.341-7.205) compared to infection-naïve persons (1.842 26 BAU/ml, 1.019-3.116) after two doses, p<0.001. In infection-naïve persons, linear mixed effects 27 regression showed a strong negative association between age and S1 IgG one month after the first 28 vaccination (p<0.001) across the entire age range. The association was still present after the second 29 vaccination, but less pronounced. Females had higher S1 IgG than males after both the first and 30 second vaccination (p<0.001); although this difference was lower after the second dose. In persons 31 with an infection history, age nor sex was associated with peak S1 IgG. As IgG decreased with age 32 and time since vaccination, older persons may become at risk of infection, especially with escape 33 variants such as Omicron.

34 Introduction

35 Understanding and monitoring immune responses following COVID-19 vaccination is essential to 36 protect the population against severe COVID-19. The mRNA BNT162b2 vaccine was the first COVID-37 19 vaccine to be approved by the FDA and EMA, and is currently used in 159 countries around the 38 world [1]. Generally, the vaccination strategy for BNT162b2 consists of a primary series of two 39 vaccinations 3-6 weeks apart. Early studies on BNT162b2 demonstrated high vaccine efficacy against 40 COVID-19 infection after completing the full vaccination schedule [2]. This has subsequently been 41 confirmed by real-world data, considering protection against severe COVID-19 [3, 4]. 42 The elderly population is especially at risk for severe COVID-19, hospitalization and death. Age-43 related changes of the immune system, referred to as immunosenescence, contribute to the 44 increased susceptibility to infectious diseases and reduced efficacy of vaccination in elderly persons 45 [5, 6]. Others have shown impaired immune responses following COVID-19 vaccination when 46 comparing data from elderly nursing home residents to those from younger healthcare workers [7, 47 8]. However, apart from difference in age range, these specific groups differ considerably from the 48 general population in terms of health status. Further data for elderly people outside of nursing home 49 settings are lacking [9]. Thus, data on the peak antibody concentrations post vaccination in the 50 general population as a whole remains limited [10, 11]. This information however is essential for 51 further COVID-19 vaccination strategies to be able to better protect vulnerable groups, like the 52 elderly, against severe disease. In addition, immunity of the general population as a whole tempers 53 virus transmission which further lowers the overall disease burden. 54 In the Netherlands, COVID-19 vaccinations were offered from early 2021 onwards. Initially, priority 55 was given to frontline healthcare workers and individuals at high risk for severe COVID-19 due to 56 long-term health conditions. Afterwards, the general population was invited for vaccination, 57 descending by age. Currently, everyone 5 years or older has access to free COVID-19 vaccination. 58 The most commonly used vaccine for all ages is BNT162b2, except those aged 60-64. This group 59 mostly received Vaxzevria as their primary vaccination series due to national policies at the time. 60 In this article we discuss COVID-19 serological findings across 1 735 persons in the Dutch general 61 population with an age range of 12 to 92 years following a primary series of BNT162b2. We 62 determined the effect of age and sex on antibody acquisition up to one month following one and 63 two doses of BNT162b2, and stratified results by SARS-CoV-2 infection history. Subsequently, the 64 decay in antibody concentrations from one to three months following two doses of BNT162b2 65 vaccination were analysed for persons aged 50 and over.

66

67 Methods

68 Study population

Data from two observational, longitudinal COVID-19 vaccination cohort studies with the same study

- design were combined: one focusing on adolescents and adults (12 to 60 years old) and one on the
- ageing population (50+ years old). Participants were included in the study if they planned to receive
- 72 COVID-19 vaccination or completed the primary vaccination series within the last 28 days, as this
- vas the primary endpoint of the study. See Supplementary Material for further details on study
- 74 design, recruitment and inclusion and exclusion criteria.

75 Sample collection

- 76 Finger-prick blood samples and questionnaires were taken at four time points; prior to COVID-19
- vaccination (Pre-vacc), 28 days after the first vaccination (Dose 1), 28 days after the second
- vaccination (Dose 2), and three months after the second vaccination (Month 3). Month 3 data was
- 79 only available for the 50+ cohort. Questionnaires covered demographic factors, COVID-19
- 80 vaccination information (brand and dates), and SARS-CoV-2 testing information (if applicable).
- 81 Finger-prick blood samples were self-collected in microtubes and returned by mail. Once received at
- 82 the laboratory at the National Institute of Public Health and the Environment (RIVM), the
- 83 Netherlands, serum was isolated from each sample by centrifuge and stored at -20°C until sample
- 84 processing.

85 Immunoglobulin G detection

- 86 Total immunoglobulin G (IgG) antibody concentrations to Spike S1 and Nucleoprotein were
- 87 measured simultaneously using a bead-based assay as previously described [12]. IgG concentrations
- 88 were expressed as binding antibody units per mL (BAU/ml) using 5-parameter logistic interpolation
- of the International Standard for human anti-SARS-CoV-2 immunoglobulin (20/136 NIBSC standard)
- 90 [13]. The threshold for seropositivity was set at 10.1 BAU/ml for Spike S1 [14] and 14.3 BAU/ml for
- 91 Nucleoprotein [15].

92 Statistical analyses

- 93 All statistical analyses were performed in RStudio (version 4.1.3) [16]. Age in years at first
- 94 vaccination was used. Persons who received one or two doses of BNT162b2 were selected. Persons
- 95 who received BNT162b2 in a heterologous schedule were excluded from analysis. Samples were
- 96 included if they were within -7 or +7 days from day 28 (Dose 1), -14 or +14 days from day 28 (Dose

97 2), and -14 or +14 days from three months (Month 3). Persons with serological evidence of a SARS-98 CoV-2 infection history (i.e., seropositive to Spike S1 at Pre-vacc) and/or a self-reported positive 99 SARS-CoV-2 test performed by local health authorities prior to their vaccination schedule were 100 analysed separately. SARS-CoV-2 confirmatory testing was available free of charge to anyone with 101 COVID-19 related symptoms or those who were in close contact with someone who had tested 102 positive according to national guidelines in the Netherlands. Persons who reported a positive SARS-103 CoV-2 test during - or following, for the 50+ cohort - their vaccination schedule were excluded. 104 Participants who were seronegative for Spike S1 but seropositive for Nucleoprotein at Pre-vacc were 105 also excluded as their infection-status was considered non-conclusive. Flowcharts of the number of 106 participants and available samples are shown in Supplementary Figure 1. 107 The Mann-Whitney-test was used to compare antibody concentrations between groups. A linear 108 mixed effects regression model with a random intercept per participant was used to determine the 109 effect of timepoint, age and sex on S1 IgG concentrations using *lme4* (version 1.1.28 [17]). A model 110 with these explanatory variables as well as an interaction term between timepoint and age and 111 timepoint and sex was created. Separate models were built for infection-naïve persons and those 112 with a history of SARS-CoV-2 infection. The Pre-vacc timepoint was not included in the model for 113 infection-naïve participants as we assumed no effect of age and sex on seronegative IgG S1 114 concentrations. Backward stepwise model selection was performed and the model with the lowest 115 Akaike Information Criterion (AIC) was selected using the step function within ImerTest. S1 IgG 116 concentrations were log10-transformed for regression models. Two additional models were built to 117 assess antibody production following first vaccination, and then to assess decay following 118 completion of the primary vaccination series. The former model used data from infection-naïve 119 participants with measurements at both Dose 1 and Dose 2, and the latter model used data from 120 infection-naïve participants with measurements at both Dose 2 and Month 3. In addition to age and 121 sex, we explored the effect of antibody concentrations produced at a previous timepoint on the fold-122 change to the next timepoint; e.g. the effect of IgG S1 concentrations at Dose 1 on the fold-change 123 of antibody concentrations between Dose 1 and Dose 2. Fold-change was calculated with IgG S1 124 concentrations on the linear scale. Linear regression was conducted using age, sex and IgG 125 concentration as explanatory variables, as well as the interactions between these variables. Final 126 model selection was based on the AIC, as described above.

127 *Ethics statement*

Ethical approval was obtained through The Medical Research Ethics Committee Utrecht for both the
 50+ population cohort (NL74843.041.21, EudraCT: 2021-001976-40), and for the adolescent and

| 130 | adult cohort (12-60 years) (NL76440.041.21, EudraCT: 2021-001357-31). All participants provided |
|-----|---|
| 131 | written informed consent. In the case of participants aged 12 till 16, both parents also provided |
| 132 | written informed consent |

133

134 Results

135 Study population

- 136 A total of 1.735 BNT162b2-vaccinated participants were included and 4.925 measurements were
- available: 1.377 at Pre-vacc, 1.429 at Dose 1, 1.425 at Dose 2 and 694 at Month 3 (50+ cohort only).
- 138 As vaccines were rolled-out per age group from old to young according to the national vaccination
- 139 campaign, older persons were less likely to have a pre-vaccination measurement. Twenty-two
- 140 participants dropped out of the study after enrolment. Overall, more females than males were
- included (1.036; 60% vs 687; 40%). The median interval between the two vaccination doses was 35
- days (interquartile range, IQR: 35-35) and did not differ between age groups (Supplementary Table
- 143 1). In the ages 20-59 years old, approximately 20% had a SARS-CoV-2 infection prior to vaccination,
- followed by 12% for the ages 12-19, 5% for the ages 60-79 and 0% in 80+ (Supplementary Table 1).

145 Higher Spike S1-specific IgG in persons with a history of SARS-CoV-2 infection

146 At Dose 1, 97% (1·204/1·235) were seropositive among infection-naïve persons and 100% (193/194) 147 among those with an infection prior to vaccination. Seropositivity at Dose 1 decreased with age 148 (Supplementary Table 2). Seropositivity was 100% at Dose 2 irrespective of age and prior infection 149 status. For all ages, median S1 IgG in infection-naïve increased from 0 BAU/ml Pre-vacc (IQR: 0-1), to 150 146 BAU/ml at Dose 1 (72-290; Pre-vacc vs. Dose 1: p<0.001), and further to 1.842 BAU/ml at Dose 2 151 (1.019-3.116; Dose 1 vs. Dose 2: p<0.001), Figure 1. Persons who experienced a SARS-CoV-2 infection 152 prior to vaccination increased from 73 BAU/ml Pre-vacc (29-147), to 3 293 BAU/ml at Dose 1 (1 191-153 5·751; Pre-vacc vs. Dose 1: p<0.001) and 4·535 BAU/ml at Dose 2 (2·341-7·205; Dose 1 vs. Dose 2: 154 p=0.002); their S1 IgG was higher compared to infection-naïve participants at each timepoint 155 (p<0.001).

156 Age is a strong indicator of Spike S1-specific IgG acquisition following vaccination

- 157 BNT162b2-induced S1 IgG upon vaccination decreased in concentration with age, with the highest
- 158 concentrations in the age group 12-19 years old (Dose 1: median 526 BAU/ml, 282-770 and Dose 2:
- 159 median 4·198 BAU/ml, 2·692-6·131). We observed stepwise drops per age decade to a median
- 160 concentration of 45 BAU/ml (16-113) for Dose 1 and a median concentration of 672 BAU/ml (366-
- 161 1·304) for Dose 2 in the 80-92 age group (see Figure 2 and Supplementary Table 2). There was a

162 strong negative association between age and IgG concentration at Dose 1 and Dose 2 (Table 1 and 163 Figure 3). The strength of the negative association between age and S1 IgG concentration decreased 164 between Dose 1 and Dose 2, indicating greater antibody acquisition with increasing age between 165 Dose 1 and Dose 2 (coefficient of interaction term age*Dose 2: 0.004; p<0.001), Table 1. Females 166 had higher IgG S1 concentrations compared to males at Dose 1 (0.093; p<0.001), but this difference 167 was smaller at Dose 2 (coefficient of interaction term Female*Dose 2: -0.044; p=0.048). Lower 168 concentrations of S1 IgG at Dose 1 resulted in greater fold-change between the first and second 169 vaccination dose (Supplementary Table 3 and Supplementary Figure 2). In persons with an infection 170 history, age nor sex were associated with peak S1 IgG concentrations (Figure 2, Supplementary

171 Figure 3, Supplementary Table 4).

172 Spike S1-specific IgG decay is reduced with increasing age in persons 50 years and over

173 For infection-naïve persons in the 50+ cohort, median S1 IgG decreased from 1.304 (772-2.318) at 174 Dose 2 to 440 (239-736) at Month 3 but all participants were still seropositive at Month 3 (Figure 3C 175 and Supplementary Table 2). The strength of the negative association between age and S1 IgG was 176 lower at Month 3 compared to Dose 2, indicating slower antibody decay with increasing age 177 between Dose 2 and Month 3 (coefficient for interaction term age*Month 3: 0.004; p<0.001, Figure 178 3D and Supplementary Table 5). The coefficient for higher S1 lgG in females compared to males 179 remained the same between Dose 2 and Month 3 (0.102; p<0.001). For antibody loss – i.e., the fold-180 change between one and three months following the second vaccination – higher concentrations of 181 IgG S1 at Dose 2 resulted in a greater loss (Figure 4 and Supplementary Table 6). For females, 182 antibody loss was faster than for males at high concentrations of Dose 2 IgG S1 but slower at low 183 concentrations of Dose 2 IgG S1. In persons with an infection history, neither age nor sex were 184 associated with S1 IgG concentrations at both post-vaccination timepoints (Supplementary Figure 3 185 and Supplementary Table 5).

186

187 Discussion

Here we show high peak IgG responses to Spike S1 following two doses of BNT162b2 in infectionnaïve persons from the general population across a wide age range of 12 to 92 years. At the time of writing, this study is unique as it includes people of all ages, enabling direct comparison of S1 antibodies in adolescents, adults and the elderly. The large numbers of participants in this study allowed us to demonstrate a strong negative association between IgG S1 concentrations and age after the first dose of BNT162b2. This association was less pronounced but still present after the

second dose. In general, the primary vaccination series resulted in high peak antibody concentrationeven in the oldest persons.

196 We showed that IgG concentrations one month after the first dose were negatively associated with 197 age. This may be due to an overall superior B cell function in younger persons, possibly involving a 198 broader repertoire of naïve B cells. These cells are more quickly activated upon exposure to the 199 novel antigen introduced by the vaccine. Additionally, antigen uptake, processing, presentation, and 200 signalling of innate cells, as well as recruiting T cell help are more efficient in the young. This may 201 contribute to higher antibody concentrations upon initial vaccination in younger persons [18, 19]. 202 However, the increase in antibody concentrations induced by the second vaccine dose was greater 203 with increasing age, partly compensating the lower antibody acquisition after the first dose. One 204 explanation might be that high concentrations of circulating IgG – seen in younger persons – could 205 partially blunt the response to the second vaccine dose and thus limit restimulation of antibody 206 production following the second vaccine dose. Specifically, considering the relatively short 207 vaccination interval of five weeks. Another explanation might be that peak antibody production was 208 not yet achieved in older persons one month after the first vaccination dose. Interestingly, we also 209 demonstrated that antibody loss between one and three months following the second dose was 210 slower with older age in the 50+ cohort. This could be explained by IgG half-life which affects lower 211 IgG values in older persons less than higher IgG values in younger persons, and by differences in 212 underlying short-lived plasma cell responses and memory B cell formation across age ranges [19, 213 20].

214 Other studies have previously shown the inverse relationship between age and antibody 215 concentrations following one dose of BNT162b2 in the infection-naïve general population or 216 healthcare workers [7, 11]. However, observations of antibody concentrations following two doses 217 are contradictory, with some studies reporting limited to no effect [7, 9] and others strong 218 associations with age [10, 21-24]. The lack of an observed age-association after two doses reported 219 in some studies might be explained by the serological assay used, the time window of sampling since 220 the second dose, the time interval between the two doses, and/or the sample size of the study. The 221 sample size in this study was large across all ages with well-defined sampling times post-vaccination. 222 However, it should be noted that persons of 60-64 years old were underrepresented in our study 223 due to national guidelines to vaccinate with Vaxzevria. The pronounced age-effect demonstrated in 224 this study was still present one month after the second dose, and for the 50+ cohort at three months 225 following the second dose. This is in line with results from a recent pre-print showing lower vaccine 226 effectiveness against SARS-CoV-2 infection to the Delta and Omicron BA.1 variants with increasing 227 age in the Netherlands [25]. Nevertheless, infection risk is determined by a complex interaction of

infection pressure, behaviour, and the immune system's response to invasion of the virus, which of
 course constitutes more than antibody concentrations alone.

230 To date, most data on antibody responses following BNT162b2 vaccination in the elderly (80+) were 231 derived from nursing home residents, the most frail group of older individuals [7, 8]. The ageing 232 population, however, shows a huge heterogeneity in health status, with early signs of ageing already 233 occurring in the 5th decade (40-50) of life [26]. The diversity between individuals is caused by a 234 complex interplay of physiological and maybe pathological changes in metabolism, organ function, 235 the innate and adaptive immune system, and differences in exposure to risk factors [18]. In nursing 236 home residents aged 80 and over the seroconversion rate for Spike S1 following the primary series 237 of BNT162b2 was 89% [8]. Here, we showed 100% seropositivity in the elderly general population, 238 outside of nursing home settings, up to three months following the second vaccine dose. 239 Reassuringly, this implies that in a large part of the older general population immune response is 240 better when compared to older persons in nursing homes. Similarly, Parry et al. also studied persons

ages 80 and over in the general population and showed a seroconversion rate of 96% after two

242 doses of BNT162b2 (n= 100) [9].

As previously described by others, we showed that females had slightly higher antibody

concentrations than males following BNT162b2 vaccination [10, 11, 22]. This has been hypothesized

to be due to sex steroid hormones or other genetic factors [5, 6]. Also in line with previous findings,

246 we showed higher antibody concentrations in participants with a history of SARS-CoV-2 infection

247 [10, 11, 27]. This finding has led to a national recommendation in The Netherlands of requiring a

single dose to complete the primary vaccine series in persons with previous SARS-CoV-2 infection.

249 We found that peak IgG S1 concentrations one month after the second dose were not affected by

age or sex in persons with an infection history. However, in the 50+ cohort at three months following

the second dose there was more variation in IgG concentrations, but also fewer observations

available across a smaller age range. Still, the persistence of antibodies may differ for those receiving

253 one or two doses following infection, or with age and sex.

In conclusion, we showed a strong negative association between BNT162b2-vaccination induced S1

255 IgG concentration and age. High concentrations of circulating antibodies are important for

256 neutralizing SARS-CoV-2 infection, as also recently exemplified by escape variants such as Omicron.

257 Monitoring the persistence or decay of immune responses following vaccination is pivotal,

258 specifically to evaluate antibody concentrations associated with immune protection in the elderly

259 population. Such knowledge could support vaccination strategies to sustain optimal population

- 260 immunity. Therefore, future work will focus on vaccine-induced SARS-CoV-2 humoral and cellular
- 261 responses over time across age, infection history, number of received doses and health status.
- 262
- 263 Funding
- 264 This work was funded by the Dutch Ministry of Health, Welfare and Sports.
- 265

266 Acknowledgements

267 We would like to thank all participants.

268 References

| 269 270 | 1. | Shrotri, M., et al., <i>An interactive website tracking COVID-19 vaccine development.</i> Lancet | | | |
|------------|-----|---|--|--|--|
| 270 | 2. | Polack, F.P., et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J | | | |
| 272 | | Med, 2020. 383 (27): p. 2603-2615. | | | |
| 273 | 3. | Haas, E.J., et al., Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 | | | |
| 274 | | infections and COVID-19 cases, hospitalisations, and deaths following a nationwide | | | |
| 275 | | vaccination campaign in Israel: an observational study using national surveillance data. | | | |
| 276 | | Lancet, 2021. 397 (10287): p. 1819-1829. | | | |
| 277 | 4. | Tartof, S.Y., et al., Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a | | | |
| 278 | | large integrated health system in the USA: a retrospective cohort study. Lancet, 2021. | | | |
| 279 | | 398 (10309): p. 1407-1416. | | | |
| 280 | 5. | Ciabattini, A., et al., <i>Vaccination in the elderly: The challenge of immune changes with aging.</i> | | | |
| 281 | | Semin Immunol, 2018. 40 : p. 83-94. | | | |
| 282 | 6. | Poland, G.A., I.G. Ovsyannikova, and R.B. Kennedy, Personalized vaccinology: A review. | | | |
| 283 | | Vaccine, 2018. 36 (36): p. 5350-5357. | | | |
| 284 | 7. | Faro-Viana, J., et al., Population homogeneity for the antibody response to COVID-19 | | | |
| 285 | | BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age | | | |
| 286 | | ranges. Nat Commun, 2022. 13 (1): p. 140. | | | |
| 287 | 8. | Muller, L., et al., Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 | | | |
| 288 | | Coronavirus Disease 2019 Vaccination. Clin Infect Dis, 2021. 73(11): p. 2065-2072. | | | |
| 289 | 9. | Parry, H., et al., mRNA vaccination in people over 80 years of age induces strong humoral | | | |
| 290 | | immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. | | | |
| 291 | | Elife, 2021. 10 . | | | |
| 292 | 10. | Wei, J., et al., Antibody responses and correlates of protection in the general population after | | | |
| 293 | | two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med, 2022. | | | |
| 294 | 11. | Wei, J., et al., Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general | | | |
| 295 | | population of the United Kingdom. Nat Microbiol, 2021. 6(9): p. 1140-1149. | | | |
| 296 | 12. | den Hartog, G., et al., SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A | | | |
| 297 | | Multiplex Analysis Approach Accounting for Accurate Seroprevalence. J Infect Dis, 2020. | | | |
| 298 | | 222 (9): p. 1452-1461. | | | |
| 299 | 13. | World Health Organization. First WHO International Standard for anti-SARS-CoV-2 | | | |
| 300 | | immunoglobulin (human). 2020 [cited 2021 7 June 2021]; Available from: | | | |
| 301 | | https://www.nibsc.org/documents/ifu/20-136.pdf | | | |
| 302 | 14. | Vos. E.R.A., et al., Associations between measures of social distancing and SARS-CoV-2 | | | |
| 303 | | seropositivity: a nationwide population-based study in the Netherlands. Clin Infect Dis, 2021. | | | |
| 304 | 15. | van den Hoogen, L.L., et al., Seropositivity to Nucleoprotein to detect mild and asymptomatic | | | |
| 305 | | SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID- | | | |
| 306 | | <i>19 vaccination</i> ? Vaccine. 2022. 40 (15): p. 2251-2257. | | | |
| 307 | 16. | R Core Team. R: A language and environment for statistical computing. 2020. R Foundation | | | |
| 308 | | for Statistical Computing: Vienna, Austria. | | | |
| 309 | 17. | Bates, D., et al., Fitting Linear Mixed-Effects Models Using Ime4. Journal of Statistical | | | |
| 310 | | Software, 2015. 67 : p. 1-48. | | | |
| 311 | 18. | Pinti, M., et al., Aging of the immune system: Focus on inflammation and vaccination. Eur J | | | |
| 312 | | Immunol. 2016. 46 (10): p. 2286-2301. | | | |
| 313 | 19. | Siegrist, C.A. and R. Aspinall. <i>B-cell responses to vaccination at the extremes of age</i> . Nat Rev | | | |
| 314 | | Immunol, 2009. 9 (3): p. 185-94. | | | |
| 315 | 20. | Steenhuis, M., et al., Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. | | | |
| 316 | | Clin Transl Immunology, 2021. 10 (5): p. e1285. | | | |
| 317 | 21. | Bates, T.A., et al., Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine | | | |
| 318 | | Immune Serum Samples. JAMA, 2021. | | | |

- Levin, E.G., et al., Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6
 Months. N Engl J Med, 2021. 385(24): p. e84.
- Naaber, P., et al., Dynamics of antibody response to BNT162b2 vaccine after six months: a
 longitudinal prospective study. Lancet Reg Health Eur, 2021. 10: p. 100208.
- 32324.Pellini, R., et al., Initial observations on age, gender, BMI and hypertension in antibody324responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine, 2021. 36: p. 100928.
- Andeweg, S.P., et al., Protection of COVID-19 vaccination and previous infection against
 Omicron BA.1 and Delta SARS-CoV-2 infections, the Netherlands, 22 November 2021-19
 January 2022. MedRxiv, 2022.
- Herndler-Brandstetter, D., H. Ishigame, and R.A. Flavell, *How to define biomarkers of human T cell aging and immunocompetence*? Front Immunol, 2013. 4: p. 136.
- van den Hoogen, L.L., et al., SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA
 or vector-based vaccination in the general Dutch population show distinct kinetics. Sci Rep,
 2022. 12(1): p. 5935.

333

335 Table 1: Linear mixed effects regression results for Spike S1 IgG concentrations up to one month

following two doses of BNT162b2 for infection-naïve persons. Model results for 1.448 unique

- participants with S1 IgG measurements available at one month after the first (Dose 1) or second
- 338 vaccination dose (Dose 2). Three persons reporting their sex as "other" were excluded from the
- 339 model.

| | Coefficient | 95% Cl | p-value |
|-----------------|-------------|---------------|---------|
| Timepoint | | | |
| - Dose 1 | Ref. | | |
| - Dose 2 | 0.891 | 0.822,0.960 | <0.001 |
| Age in years | -0.013 | -0.014,-0.012 | <0.001 |
| Sex | | | |
| - Male | Ref. | | |
| - Female | 0.093 | 0.049,0.136 | <0.001 |
| Age*Dose 2 | 0.004 | 0.003,0.006 | <0.001 |
| Sex*Dose 2 | | | |
| - Male*Dose 2 | Ref. | | |
| - Female*Dose 2 | -0.044 | -0.087,-0.000 | 0.049 |

340

342 Figure legends

343 Figure 1: Spike S1-specific IgG kinetics following the primary series of BNT162b2 vaccination in 344 infection-naïve participants (A) and participants with a SARS-CoV-2 infection prior to vaccination 345 (B). Boxplots show results for all participants at each timepoint, while dots and dashed grey lines 346 show measurements and their trajectory between timepoints per participant. Results are shown for 347 total of 1.500 infection-naïve participants and 235 participants with a SARS-CoV-2 infection history; 348 measurements were not available at every timepoint for each participant. Spike S1 IgG 349 concentrations were expressed in international binding antibody units (BAU) using the 20/136 NIBSC 350 standard and were taken prior to vaccination (Pre-vacc), one month following the first (Dose 1) and 351 one month following the second vaccination dose (Dose 2). The horizontal dashed line represents 352 the threshold for seropositivity to Spike S1. Asterisks indicate p-values from Wilxocon-Mann 353 Whitney test (unpaired), when the Wilcoxon signed ranks test was performed in only paired 354 samples all p-values were <0.001. lgG: immunoglobulin G; BAU: binding antibody units; ***: 355 p<0.001; **: p=0.002.

356 Figure 2: Spike S1-specific IgG kinetics by age category following the primary series of BNT162b2

357 vaccination in infection-naïve participants (A) and participants with a SARS-CoV-2 infection prior

358 to vaccination (B). Boxplots show results by age group at each timepoint, while dots show individual

359 measurements. Results are shown for total of 1.500 infection-naïve participants and 235 participants

360 with a SARS-CoV-2 infection history; measurements were not available at every timepoint for each

361 participant (see Supplementary Table 2). Spike S1 IgG concentrations were expressed in

international binding antibody units (BAU) using the 20/136 NIBSC standard and were taken prior to
 vaccination (Pre-vacc), one month following the first (Dose 1) and one month following the second
 vaccination dose (Dose 2). The horizontal dashed line represents the threshold for seropositivity to
 Spike S1. IgG: immunoglobulin G; BAU: binding antibody units.

366 Figure 3: Spike S1-specific IgG by age in years per timepoint (A,B,D) and kinetics following the

367 primary series of BNT162b2 vaccination in infection-naïve participants up to three months

368 **following the second vaccination dose (C).** In (A, B, D) fitted lines represent the linear association

between IgG concentration and age from linear mixed effects regression results (see Table 1 and

370 Supplementary Table 4), while dots represent individual measurements. Results are shown

371 separately for males (green) and females (yellow). In (C) boxplots show results for all participants at

are each timepoint, while dots and dashed grey lines show measurements and their trajectory between

373 timepoints per participant. In (A-D) Spike S1 IgG concentrations were expressed in international

binding antibody units (BAU) using the 20/136 NIBSC standard and were taken prior to vaccination

- 375 (Pre-vacc), one month following the first (Dose 1), one month following the second (Dose 2) or three
- 376 months following the second vaccination dose (Month 3). In (A-B) results are shown for total of
- 377 1.448 unique infection-naïve participants across all ages with S1 IgG measurements available at Dose
- 378 1 and/or Dose 2, while in (C) results are shown for 749 unique infection-naïve participants in the 50+
- 379 cohort and in (D) results are shown for 725 unique infection-naïve participants in the 50+ cohort
- 380 with measurements available at Dose 2 and/or Month 3. The horizontal dashed line represents the
- 381 threshold for seropositivity to Spike S1. IgG: immunoglobulin G; BAU: binding antibody units.
- 382 Figure 4: The fold-change in Spike S1-specific IgG to represent antibody loss between one and
- 383 three months following the second dose of BNT162b2 by IgG S1 concentration at one month
- 384 **following the second dose.** Fitted lines represent the linear association between fold-change and
- 385 age from linear mixed effects regression results for four ages (see Supplementary Table 6), while
- dots represent individual measurements. Results are shown separately for males and females. This
- 387 only includes participants who participated at both timepoints (i.e., one month and three months
- following the second dose of BNT162b2); n=633.









